In June 2025, the National Blood Authority (NBA) finalised a procurement for new national contracts for the supply of several products used for the treatment of haemophilia A and B. The procurement resulted in the establishment of contracts with five companies: Sanofi-Aventis Australia Pty Ltd, Takeda Pharmaceuticals Australia Pty Ltd, Pfizer Australia Pty Ltd and CSL Behring (Australia) Pty Ltd for the supply of recombinant Factor VIII (rFVIII) and recombinant Factor IX (rFIX), and Roche Products Australia Pty Ltd for the supply of emicizumab (Hemlibra), a monoclonal antibody.
The new supply arrangements, summarised in the table below, will commence from 1 July 2025 and will continue for a period of up to five years, including available extension options. All current products will continue to be available under the new arrangements, other than Advate, a standard half-life (SHL) rFVIII. Advate will remain available temporarily for a period following 1 July, with further details to follow on timing and transition arrangements.
In addition to the current products, extended half-life (EHL) rFIX product Idelvion will become available under the new arrangements. Further details on the timing of Idelvion availability will follow.
The NBA has negotiated robust arrangements that continue to uphold security of supply through a diversity of available products and suppliers, to ensure the best outcomes for Australian patients.
The products available under the supply arrangements are as follows:
Product type | Product name |
| SHL rFVIII | Xyntha (Pfizer Australia Pty Ltd) |
| EHL rFVIII | Adynovate (Takeda Pharmaceuticals Australia Pty Ltd) Eloctate (Sanofi-Aventis Australia Pty Ltd) |
| SHL rFIX | Benefix (Pfizer Australia Pty Ltd) |
| EHL rFIX | Alprolix (Sanofi-Aventis Australia Pty Ltd) Idelvion (CSL Behring (Australia) Pty Ltd) |
| Monoclonal antibody | Hemlibra (Roche Products Australia Pty Ltd) |
Last updated: 01 Jul 2025